Multiplex TALEN Gene-Editing for the Next Generation of CAR-T Cells in Solid Tumors

Time: 11:00 am
day: Day Two


  • Gene editing allows expanding the success of allogeneic CAR-T therapies in hematological malignancies to solid tumors
  • Exploring various immune scenarios is needed depending on diseases/patient populations
  • TALEN®-mediated highly efficient complex engineering allows programming of these immune scenarios into allogeneic CAR-T cells to optimize persistence, potency, and safety